UBS Downgrades Coherus BioSciences to Neutral, Lowers Price Target to $1.5
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Ashwani Verma has downgraded Coherus BioSciences (NASDAQ:CHRS) from Buy to Neutral and lowered the price target from $4 to $1.5.
August 16, 2024 | 11:31 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UBS analyst Ashwani Verma downgraded Coherus BioSciences from Buy to Neutral and lowered the price target from $4 to $1.5.
The downgrade from Buy to Neutral and the significant reduction in the price target from $4 to $1.5 by UBS is likely to negatively impact investor sentiment and the stock price of Coherus BioSciences in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100